Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The Akt-GSK-3 signaling cascade in the actions of dopamine.

Beaulieu JM, Gainetdinov RR, Caron MG.

Trends Pharmacol Sci. 2007 Apr;28(4):166-72. Review.

PMID:
17349698
2.
3.

GSK-3β activity and hyperdopamine-dependent behaviors.

Li YC, Gao WJ.

Neurosci Biobehav Rev. 2011 Jan;35(3):645-54. doi: 10.1016/j.neubiorev.2010.08.001. Review. Erratum in: Neurosci Biobehav Rev. 2013 Mar;37(3):549.

4.

An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior.

Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG.

Cell. 2005 Jul 29;122(2):261-73.

5.

Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.

Cianfrocca R, Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Aug;88(8):796-801. doi: 10.1139/Y10-052.

6.

A beta-arrestin 2 signaling complex mediates lithium action on behavior.

Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG.

Cell. 2008 Jan 11;132(1):125-36. doi: 10.1016/j.cell.2007.11.041.

7.

Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.

Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, Caron MG, Javitch JA, Roth BL, Jin J.

Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93. doi: 10.1073/pnas.1104807108.

8.

Akt/GSK3 signaling in the action of psychotropic drugs.

Beaulieu JM, Gainetdinov RR, Caron MG.

Annu Rev Pharmacol Toxicol. 2009;49:327-47. doi: 10.1146/annurev.pharmtox.011008.145634. Review.

PMID:
18928402
9.

Looking at lithium: molecular moods and complex behaviour.

Beaulieu JM, Caron MG.

Mol Interv. 2008 Oct;8(5):230-41. doi: 10.1124/mi.8.5.8. Review.

PMID:
19015387
10.

Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice.

O'Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, Berry GT, Klein PS.

J Clin Invest. 2011 Sep;121(9):3756-62. doi: 10.1172/JCI45194.

11.
12.

Activation of GABA(B) receptors inhibits protein kinase B/glycogen synthase kinase 3 signaling.

Lu FF, Su P, Liu F, Daskalakis ZJ.

Mol Brain. 2012 Nov 28;5:41. doi: 10.1186/1756-6606-5-41.

13.

Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia.

Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E, Bersudsky Y, Belmaker RH, Agam G.

Int J Neuropsychopharmacol. 2008 Mar;11(2):197-205.

PMID:
17681085
14.

Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.

Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, Caron MG.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13656-61. doi: 10.1073/pnas.0803522105.

15.

Beta-arrestin 2 modulates resveratrol-induced apoptosis and regulation of Akt/GSK3ß pathways.

Sun X, Zhang Y, Wang J, Wei L, Li H, Hanley G, Zhao M, Li Y, Yin D.

Biochim Biophys Acta. 2010 Sep;1800(9):912-8. doi: 10.1016/j.bbagen.2010.04.015.

PMID:
20457218
16.

Differential effects of amisulpride and haloperidol on dopamine D2 receptor-mediated signaling in SH-SY5Y cells.

Park SW, Seo MK, Cho HY, Lee JG, Lee BJ, Seol W, Kim YH.

Neuropharmacology. 2011 Sep;61(4):761-9. doi: 10.1016/j.neuropharm.2011.05.022.

PMID:
21663752
17.

Role of Beta-arrestin 2 downstream of dopamine receptors in the Basal Ganglia.

Del'guidice T, Lemasson M, Beaulieu JM.

Front Neuroanat. 2011 Sep 6;5:58. doi: 10.3389/fnana.2011.00058.

19.
20.

beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, Lefkowitz RJ.

J Biol Chem. 2006 Jan 13;281(2):1261-73.

Items per page

Supplemental Content

Support Center